Is mavacamten available in China?

The listing process of mavacamten in China has attracted much attention. After years of research and development and clinical trials, it was finally approved by the National Medical Products Administration (NMPA) of China in April 2024 and officially launched under the trade names of Maivantol and CAMZYOS. This development marks a new option for Chinese patients in the treatment of obstructive hypertrophic cardiomyopathy (HCM).

The launch of Mavakatai not only provides patients with more effective treatment options, but also injects new vitality into the domestic heart disease treatment field. The main indication of this drug is for patients with New York Heart Association (NYHA) grade II-III obstructive hypertrophic cardiomyopathy, and can significantly improve the patient's functional status and quality of life. Its mechanism of action is to regulate the contraction and relaxation capabilities of the heart by selectively inhibiting troponin in the myocardium, thereby reducing blood flow obstruction caused by myocardial thickening.

In terms of dosage forms, Mavakatai provides capsules of 2.5 mg, 5 mg, 10 mg and 15 mg. This diverse dosage form configuration can meet the individual needs of different patients, allowing doctors to make more precise medication adjustments according to the specific conditions of the patients. At the same time, as the market is launched, relevant education and promotion activities will be gradually launched to increase the understanding and use of this drug by medical professionals and patients.

In the long run, the launch of Mavaceta will have a profound impact on the treatment of cardiovascular diseases in China. As a common hereditary heart disease, the treatment options for hypertrophic cardiomyopathy are relatively limited, so the emergence of new drugs has greatly enriched the treatment options. For many patients who are unable to fully participate in daily activities due to the limitations of their condition, Mavakate offers hope and can help them regain a normal life.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK582152/